FLT3 and acute myeloid leukemia: In the RADIUS trial, a phase II randomized study to investigate the role of midostaurin maintenance, an early report found a benefit to adding midostaurin to SOC as a maintenance treatment in patients with FLT3-ITD AML after allogenic HSCT (19).